New drug trial offers hope for patients with rare, painful joint tumors
NCT ID NCT04488822
Summary
This study is testing whether the drug pexidartinib can shrink tumors and improve joint movement in adults with a rare, non-cancerous joint tumor called tenosynovial giant cell tumor (TGCT). The trial is for people whose condition causes severe pain or limits their movement and cannot be improved with surgery. Participants will take the drug daily and be monitored for tumor response, side effects, and changes in their physical function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Ji Shui Tan Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
National Taiwan University Hospital
Taipei, Taiwan
-
Peking University Cancer Hospital
Beijing, China
-
Shanghai General Hospital
Shanghai, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China
Conditions
Explore the condition pages connected to this study.